Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving Soleno Therapeutics, Inc. and may file a class action lawsuit on behalf of investors [1][2]. Company Developments - On March 26, 2025, Soleno Therapeutics announced FDA approval for VYKAT XR (diazoxide choline) extended-release tablets aimed at treating hyperphagia in individuals with Prader-Willi syndrome aged 4 and older [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed that the discontinuation rate for VYKAT XR due to adverse effects was approximately 8% by the end of Q3 fiscal 2025 [3]. - CEO Anish Bhatnagar acknowledged a disruption in the launch trajectory of VYKAT XR following a short seller report released in mid-August, which resulted in a decrease in start forms and an increase in discontinuations for non-serious adverse events [3]. - Following these developments, Soleno's share price experienced a decline of over 26% [3].